Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2023
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Deal Size : Inapplicable
Deal Type : Inapplicable
Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche’s Enspryng Leads Latest CHMP Recommendations
Details : Leading those recommendations is Roche’s Enspryng (satralizumab), which received a positive opinion for the treatment of the rare autoimmune disease neuromyelitis optica spectrum disorders (NMOSD).
Product Name : Enspryng
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacopan,Azathioprine,Rituximab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group.
Product Name : Tavneos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Avacopan,Azathioprine,Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacopan,Azathioprine,Rituximab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study showed that avacopan was as effective as prednisone therapy in bringing patients into remission by 26 weeks, and superior to prednisone for sustained remission after 52 weeks.
Product Name : Tavneos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : Avacopan,Azathioprine,Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacopan,Azathioprine,Rituximab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : If approved, avacopan would be the first orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Product Name : Tavneos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2020
Lead Product(s) : Avacopan,Azathioprine,Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azathioprine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Medicines Evaluation Unit | Syne Qua Non Limited | Alderley Analytical | Black County Pathology Services | Diamond Pharma Services | Boyd Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2019
Lead Product(s) : Azathioprine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Medicines Evaluation Unit | Syne Qua Non Limited | Alderley Analytical | Black County Pathology Services | Diamond Pharma Services | Boyd Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Celltrion
Deal Size : Inapplicable
Deal Type : Inapplicable
Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2015
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Celltrion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2015
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2013
Lead Product(s) : Azathioprine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable